Progress in evaluating the status of hepatitis C infection based on the functional changes of hepatic stellate cells (Review)

Wang, Wei; Huang, Xuelian; Fan, Xuzhou; Yan, Jun; Luan, Jianfeng

doi:10.3892/mmr.2020.11516

Cited by 6 publications

(3 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C Virus (HCV) causes viral hepatitis characterized by acute liver inflammation to severe conditions like liver cirrhosis, hepatic encephalopathy, liver failure, hepatorenal syndrome and hepatocellular carcinoma [35] , [36] . About 55–85% of infected HCV patients develop chronic infection which is associated with the incidence of liver cancer [37] , [38] .…”

Section: Discussionmentioning

confidence: 99%

Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches

Kamboj

Rajput

Rastogi

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches

Kamboj

Rajput

Rastogi

et al. 2022

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…This disease can have various outcomes, ranging from mild (minimal inflammation of the liver) to severe, and can lead to scar tissue formation. Chronic infection eventually causes cirrhosis, leading to hepatocellular carcinoma and, ultimately, death [8]. A report from the Centers for Disease Control and Prevention (CDC) states that HCV-related cirrhosis is observed in 5-20% of patients experiencing chronic HCV infections over a prolonged period of 20-30 years.…”

Section: Introductionmentioning

confidence: 99%

Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections

2022

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infections are emerging as one of the foremost challenges in healthcare owing to its chronicity and the virus's quasispecies nature. Worldwide, over 170 million people are chronically infected with HCV, with an annual mortality of over 500,000 people across the world. The emerging pathophysiological evidence links HCV infections to a risk of developing liver diseases such as cirrhosis and hepatocellular carcinoma. Despite the great strides that have been made towards understanding the pathophysiology of disease progression, the tailored treatments of HCV infection remain to be established. The present review provides an update of the literature pertaining to evolving therapeutic approaches and prophylactic measures for the effective management of HCV infections. An extensive discussion of established and experimental immune prophylactic measures also sheds light on current developments in the design of vaccination strategies against HCV infection. We have also attempted to address the application of nanotechnology in formulating effective therapeutic interventions against HCV. Pointing out the limitations of the existing diagnostic methods and therapeutic approaches against HCV might inspire the design and development of novel, efficient, reliable, and cost-effective diagnostic technologies as well as novel therapeutic and immune prophylactic interventions for the effective management of HCV.

show abstract

“…HCV activates HSCs through the production of viral proteins that directly and indirectly stimulate HSCs to develop into abnormally overgrown myofibroblasts that do not degrade normally, causing scarring of the liver and eventually cirrhosis [ 2 ]. The release of microRNAs, interleukins (ILs), chemokines, inflammatory factors, neuroendocrine signals and oxidative stress markers regulate this crossover of HSCs to myofibroblasts [ 2 , 8 , 9 ]. While the macrocellular processes involved in cirrhosis have been the focus of several studies, many of the microcellular and immunological components regulating progression from chronic HCV infection to cirrhosis or from cirrhosis to HCC remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort

Argirion

Brown

Jackson

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Chronic hepatitis C virus (HCV) infection can affect immune response and inflammatory pathways, leading to severe liver diseases such as cirrhosis and hepatocellular carcinoma (HCC). Methods: In a prospective cohort of chronically HCV-infected individuals, we sampled 68 individuals who developed cirrhosis, 91 controls who did not develop cirrhosis, and 94 individuals who developed HCC. Unconditional odds ratios (ORs) from polytomous logistic regression models and canonical discriminant analyses (CDAs) were used to compare categorical (C) baseline plasma levels for 102 markers in individuals who developed cirrhosis vs. controls and those who developed HCC vs. cirrhosis. Leave-one-out cross validation was used to produce receiver operating characteristic curves to assess predictive ability of markers. Lastly, biological pathways were assessed in association with cirrhotic development compared to controls. Results: After multivariable adjustment, DEFA-1 (OR: C2v.C1 = 7.73; p < 0.0001), ITGAM (OR: C2v.C1 = 4.03; p = 0.0002), SCF (OR: C4v.C1 = 0.19; p-trend = 0.0001), and CCL11 (OR: C4v.C1 = 0.31; p-trend= 0.002) were all associated with development of cirrhosis compared to controls; these markers, together with clinical/demographics variables, improved prediction of cirrhosis from 55.7% (in clinical/demographic-only model) to 74.9% accuracy. A twelve-marker model based on CDA results further increased prediction of cirrhosis to 88.0%. While six biological pathways were found to be associated with cirrhosis, cell adhesion was the only pathway associated with cirrhosis after Bonferroni correction. In contrast to cirrhosis, DEFA-1 and ITGAM levels were inversely associated with HCC risk. Conclusions: Pending validation, these findings highlight the important role of immunological markers in predicting HCV-related cirrhosis even 11 years post-enrollment.

show abstract

Progress in evaluating the status of hepatitis C infection based on the functional changes of hepatic stellate cells (Review)

Cited by 6 publications

References 145 publications

Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches

Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches

Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections

Association between Immunologic Markers and Cirrhosis in Individuals from a Prospective Chronic Hepatitis C Cohort

Contact Info

Product

Resources

About